fda tirzepatide news The US-FDA has approved for chronic weight management in adults with Obesity - FDA's tirzepatide decision creates uncertainty
Description
Ft: airtone

In 2010, it was initially approved as Victoza for the treatment of type 2 diabetes
The GLP-1 cons often involve nausea or mild stomach upset especially when you first start the treatment or increase your dose

JCI Insight 2018;3:e121510.ArticlePubMedPMC 16
S., et al(2023)